JP2018138049A5 - - Google Patents

Download PDF

Info

Publication number
JP2018138049A5
JP2018138049A5 JP2018088729A JP2018088729A JP2018138049A5 JP 2018138049 A5 JP2018138049 A5 JP 2018138049A5 JP 2018088729 A JP2018088729 A JP 2018088729A JP 2018088729 A JP2018088729 A JP 2018088729A JP 2018138049 A5 JP2018138049 A5 JP 2018138049A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
acid sequence
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018088729A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018138049A (ja
JP6603964B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018138049A publication Critical patent/JP2018138049A/ja
Publication of JP2018138049A5 publication Critical patent/JP2018138049A5/ja
Application granted granted Critical
Publication of JP6603964B2 publication Critical patent/JP6603964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018088729A 2011-04-26 2018-05-02 組織再生を誘導するためのペプチドとその利用 Active JP6603964B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011098270 2011-04-26
JP2011098270 2011-04-26
JP2011219454 2011-10-03
JP2011219454 2011-10-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016214996A Division JP6336549B2 (ja) 2011-04-26 2016-11-02 組織再生を誘導するためのペプチドとその利用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019175276A Division JP2020058344A (ja) 2011-04-26 2019-09-26 組織再生を誘導するためのペプチドとその利用

Publications (3)

Publication Number Publication Date
JP2018138049A JP2018138049A (ja) 2018-09-06
JP2018138049A5 true JP2018138049A5 (enExample) 2018-12-13
JP6603964B2 JP6603964B2 (ja) 2019-11-13

Family

ID=47071995

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013511983A Active JP6069191B2 (ja) 2011-04-26 2012-04-03 組織再生を誘導するためのペプチドとその利用
JP2016214996A Active JP6336549B2 (ja) 2011-04-26 2016-11-02 組織再生を誘導するためのペプチドとその利用
JP2018088729A Active JP6603964B2 (ja) 2011-04-26 2018-05-02 組織再生を誘導するためのペプチドとその利用
JP2019175276A Pending JP2020058344A (ja) 2011-04-26 2019-09-26 組織再生を誘導するためのペプチドとその利用
JP2021129955A Pending JP2021191271A (ja) 2011-04-26 2021-08-06 組織再生を誘導するためのペプチドとその利用
JP2023084251A Pending JP2023106525A (ja) 2011-04-26 2023-05-23 組織再生を誘導するためのペプチドとその利用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013511983A Active JP6069191B2 (ja) 2011-04-26 2012-04-03 組織再生を誘導するためのペプチドとその利用
JP2016214996A Active JP6336549B2 (ja) 2011-04-26 2016-11-02 組織再生を誘導するためのペプチドとその利用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019175276A Pending JP2020058344A (ja) 2011-04-26 2019-09-26 組織再生を誘導するためのペプチドとその利用
JP2021129955A Pending JP2021191271A (ja) 2011-04-26 2021-08-06 組織再生を誘導するためのペプチドとその利用
JP2023084251A Pending JP2023106525A (ja) 2011-04-26 2023-05-23 組織再生を誘導するためのペプチドとその利用

Country Status (12)

Country Link
US (4) US10364276B2 (enExample)
EP (2) EP3358011B1 (enExample)
JP (6) JP6069191B2 (enExample)
KR (2) KR101992807B1 (enExample)
CN (3) CN103687946B (enExample)
AU (4) AU2012248676B2 (enExample)
CA (1) CA2834255C (enExample)
DK (2) DK2703487T3 (enExample)
ES (2) ES2788394T3 (enExample)
PL (2) PL2703487T3 (enExample)
PT (2) PT3358011T (enExample)
WO (1) WO2012147470A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
CN102711777B (zh) 2009-10-28 2015-04-15 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
EP2913059B1 (en) 2012-10-25 2018-04-11 Genomix Co., Ltd. Novel method for treating spinal cord injury using hmgb1 fragment
RU2647467C2 (ru) 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
EP3003290B1 (en) 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
EP3291843B1 (en) * 2015-05-07 2023-03-22 University of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
JP2018536438A (ja) 2015-12-07 2018-12-13 バイオタイム,インコーポレーテッド 多様な多能性幹細胞から誘導された褐色脂肪細胞の再誘導のための方法
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ,インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
JP2019528753A (ja) * 2016-09-21 2019-10-17 スティーブン エイチ. ソーン, 高移動度グループboxi突然変異体
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
CN110621331A (zh) * 2017-04-07 2019-12-27 斯特姆里姆有限公司 纤维化疾病的治疗药物
AU2018257071B2 (en) * 2017-04-25 2021-11-11 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
EP3719117A4 (en) * 2017-12-01 2021-11-03 Stemrim Inc. EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM
US20210024594A1 (en) * 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2020071520A1 (ja) 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
CN113423466B (zh) * 2018-10-25 2025-04-25 国立大学法人大阪大学 软骨病症的治疗剂
WO2020195504A1 (ja) * 2019-03-26 2020-10-01 国立大学法人新潟大学 ペプチド及びその使用
CN109957015A (zh) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 一种hmgb1封闭性抗体的制备方法及其应用
EP4058033A1 (en) * 2019-11-12 2022-09-21 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
CN115697372A (zh) * 2020-04-03 2023-02-03 斯特姆里姆有限公司 具有间充质干细胞的动员活性的肽
WO2021215375A1 (ja) 2020-04-20 2021-10-28 塩野義製薬株式会社 Hmgb1部分ペプチドを含有する製剤
CN115361966B (zh) * 2020-04-22 2025-09-16 朱拉隆功大学 使dna恢复活力和防止dna损伤的组合物以及方法
KR102580518B1 (ko) * 2020-12-07 2023-09-21 사회복지법인 삼성생명공익재단 자가유지능이 향상된 중간엽줄기세포를 선별하는 방법 및 그에 의해 선별된 중간엽줄기세포
AU2022276188A1 (en) * 2021-05-19 2023-12-14 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
WO2023053384A1 (ja) 2021-09-30 2023-04-06 国立大学法人大阪大学 脂肪肝および非アルコール性脂肪肝炎の治療薬
CN116983471B (zh) * 2023-06-07 2024-03-08 华中科技大学同济医学院附属协和医院 一种基于α-螺旋双亲性多肽的超分子共组装凝胶的制备方法及应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (enExample) 1972-12-27 1977-09-30
US4732155A (en) 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
BR0012787A (pt) 1999-07-28 2002-07-30 Univ Leland Stanford Junior Agonistas de receptor de nicotina no recrutamento de célula tronco e de célula progenitora
WO2001032129A2 (en) 1999-11-05 2001-05-10 Gerigene Medical Corporation Augmentation and repair of age-related soft tissue defects
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EP1390058A2 (en) 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
HUP0500042A3 (en) 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
EP1459759A4 (en) 2001-11-19 2007-08-29 Kyowa Hakko Kogyo Kk MEDICAMENT FOR THE MOBILIZATION OF PLURIPOTENTIAL STEM CELLS FROM TISSUE IN THE PERIPHERAL BLOOD
US20030161816A1 (en) 2001-12-07 2003-08-28 Fraser John K. Systems and methods for treating patients with processed lipoaspirate cells
FR2833609B1 (fr) 2001-12-19 2004-12-03 Natural Implant Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations
ATE424416T1 (de) * 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
DE60327075D1 (de) 2002-07-05 2009-05-20 Univ Laval Der entzündungsreaktionen
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
NZ540067A (en) 2002-11-20 2007-05-31 Critical Therapeutics Inc A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB
WO2004061456A2 (de) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
US7632802B2 (en) 2003-03-28 2009-12-15 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
CN1193092C (zh) 2003-03-28 2005-03-16 浙江大学 骨髓间充质干细胞分离和体外扩增培养方法
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
US20090062187A1 (en) 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
EP1797118A2 (en) * 2004-09-03 2007-06-20 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006080434A1 (ja) 2005-01-27 2006-08-03 Japan Health Sciences Foundation 間葉系幹細胞を含む細胞シート
EP1893253B1 (en) 2005-03-23 2010-05-19 Biosafe S.A. Integrated system for collecting, processing and transplanting cell subsets, including adult stem cells, for regenerative medicine
KR100775958B1 (ko) * 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100280493A1 (en) 2005-06-23 2010-11-04 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
US20090155853A1 (en) * 2005-11-18 2009-06-18 Gary Nabel Non-viral gene delivery complex
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
RU2458070C2 (ru) * 2006-09-15 2012-08-10 Креабилис Терапеутикс С.П.А. Конъюгаты с полимером а-бокса hmgb1 и вариантов а-бокса hmgb1
JP5308161B2 (ja) * 2006-10-30 2013-10-09 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
CA2629652A1 (en) 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
RU2519714C2 (ru) 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
KR20110027665A (ko) 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약
WO2011046570A1 (en) 2009-10-16 2011-04-21 The University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
CN102711777B (zh) 2009-10-28 2015-04-15 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
RU2647467C2 (ru) 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
EP2913059B1 (en) 2012-10-25 2018-04-11 Genomix Co., Ltd. Novel method for treating spinal cord injury using hmgb1 fragment

Similar Documents

Publication Publication Date Title
JP2018138049A5 (enExample)
JP2023082054A5 (enExample)
JP2020518268A5 (enExample)
JP2016034981A5 (enExample)
JP2009268467A5 (enExample)
JP2021501581A5 (enExample)
JP2017532966A5 (enExample)
JP2012518420A5 (enExample)
JP2009525757A5 (enExample)
JP2012522501A5 (enExample)
JP2020520662A5 (enExample)
JP2018537087A5 (enExample)
JP2014500724A5 (enExample)
JP2018171063A5 (enExample)
JP2018520997A5 (enExample)
JP2013530689A5 (enExample)
JP2018515096A5 (enExample)
JP2019500414A5 (enExample)
JP2017018125A5 (enExample)
JP2018531624A5 (enExample)
JP2014012022A5 (enExample)
JP2012095652A5 (enExample)
JP2005120106A5 (enExample)
JP2017514522A5 (enExample)
JP2021505201A5 (enExample)